AnaptysBio, Inc. (ANAB)
54.15
-0.76
(-1.38%)
USD |
NASDAQ |
Jul 24, 16:00
53.97
-0.18
(-0.33%)
After-Hours: 20:00
AnaptysBio Enterprise Value : 1.563B for July 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 24, 2026 | 1.563B |
| July 23, 2026 | 1.585B |
| July 22, 2026 | 1.518B |
| July 21, 2026 | 1.552B |
| July 20, 2026 | 1.451B |
| July 17, 2026 | 1.675B |
| July 16, 2026 | 1.563B |
| July 15, 2026 | 1.611B |
| July 14, 2026 | 1.806B |
| July 13, 2026 | 2.018B |
| July 10, 2026 | 1.918B |
| July 09, 2026 | 1.924B |
| July 08, 2026 | 1.888B |
| July 07, 2026 | 1.945B |
| July 06, 2026 | 1.800B |
| July 02, 2026 | 1.832B |
| July 01, 2026 | 1.890B |
| June 30, 2026 | 1.950B |
| June 29, 2026 | 1.906B |
| June 26, 2026 | 1.824B |
| June 25, 2026 | 1.723B |
| June 24, 2026 | 1.689B |
| June 23, 2026 | 1.716B |
| June 22, 2026 | 1.732B |
| June 18, 2026 | 1.660B |
| Date | Value |
|---|---|
| June 17, 2026 | 1.639B |
| June 16, 2026 | 1.663B |
| June 15, 2026 | 1.719B |
| June 12, 2026 | 1.619B |
| June 11, 2026 | 1.566B |
| June 10, 2026 | 1.503B |
| June 09, 2026 | 1.490B |
| June 08, 2026 | 1.482B |
| June 05, 2026 | 1.453B |
| June 04, 2026 | 1.491B |
| June 03, 2026 | 1.478B |
| June 02, 2026 | 1.479B |
| June 01, 2026 | 1.534B |
| May 29, 2026 | 1.607B |
| May 28, 2026 | 1.646B |
| May 27, 2026 | 1.666B |
| May 26, 2026 | 1.668B |
| May 22, 2026 | 1.724B |
| May 21, 2026 | 1.745B |
| May 20, 2026 | 1.735B |
| May 19, 2026 | 1.726B |
| May 18, 2026 | 1.696B |
| May 15, 2026 | 1.824B |
| May 14, 2026 | 1.796B |
| May 13, 2026 | 1.811B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 493.07M |
| Precision BioSciences, Inc. | 115.41M |
| 4D Molecular Therapeutics, Inc. | 156.02M |
| Design Therapeutics, Inc. | 515.47M |
| Inhibrx Biosciences, Inc. | 1.210B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.88M |
| Revenue (Quarterly) | 25.56M |
| Total Expenses (Quarterly) | 78.44M |
| EPS Diluted (Quarterly) | -1.843 |
| Gross Profit Margin (Quarterly) | 97.61% |
| Profit Margin (Quarterly) | -206.9% |
| Earnings Yield | -2.00% |
| Operating Earnings Yield | 2.56% |
| Normalized Earnings Yield | -1.995 |